Home/Filings/4/0001562180-24-008599
4//SEC Filing

Semigran Marc 4

Accession 0001562180-24-008599

CIK 0001710072other

Filed

Dec 26, 7:00 PM ET

Accepted

Dec 27, 4:30 PM ET

Size

13.7 KB

Accession

0001562180-24-008599

Insider Transaction Report

Form 4
Period: 2024-12-24
Semigran Marc
Chief Development Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-12-2429,709270,291 total
    Exercise: $8.94Exp: 2032-12-30Common Stock (29,709 underlying)
  • Exercise/Conversion

    Common Stock

    2024-12-24$8.94/sh+29,709$265,59836,425 total
  • Sale

    Common Stock

    2024-12-24$29.66/sh27,980$829,9068,445 total
  • Sale

    Common Stock

    2024-12-24$30.08/sh1,729$52,0096,716 total
Footnotes (5)
  • [F1]Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
  • [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

Issuer

Edgewise Therapeutics, Inc.

CIK 0001710072

Entity typeother

Related Parties

1
  • filerCIK 0001691494

Filing Metadata

Form type
4
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 4:30 PM ET
Size
13.7 KB